title: [Usefulness of Levosimendan in patients with ventricular dysfunction before surgery].
abstract: The purpose of this work was to observe the hemodynamic stability on the first 24 hours in 4 patients with ventricular dysfunction (Ejected Fraction < 40 %), considered of high surgical risk, in which 24 at 48 hr before the surgery received an infusion of Levosimendan for 24 hours. This 4 patients was male, with age 55.5+/-7.9 years old, a left ventricle ejection of fraction (LVEF) of 31+/-5.47%; Two of them was underwent to valve replacement, another one to coronary artery bypass graft and the last one patient underwent combined procedure (coronary artery bypass graft surgery and valve replacement). The behavior of the hemodynamic parameters was stable, without necessity of uses high dose of the inotropios and classic vasopresores in the postoperative.
  
  
  CONCLUSIONS
  the Levosimendan could be an inotropic of great application in this group of patient due to its novel action mechanism and to its sustained hemodynamic effects after having finished its infusion.
authors.affiliation: Unidad de Terapia Intensiva Posquirúrgica del INCICH. lucasbauk2@yahoo.com
authors.forename: Lucas
authors.initials: L
authors.lastname: Bauk
authors.forename: Oscar Fiscal
authors.initials: OF
authors.lastname: López
authors.forename: Gustavo Sánchez
authors.initials: GS
authors.lastname: Miranda
authors.forename: Guillermo Gloss
authors.initials: GG
authors.lastname: Abdala
authors.forename: Enrique López
authors.initials: EL
authors.lastname: Mora
authors.forename: Guillermo Fernández
authors.initials: GF
authors.lastname: de la Reguera
mesh_terms: D006348:Cardiac Surgical Procedures / Q000379:methods; D002316:Cardiotonic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006331:Heart Diseases / Q000188:drug therapy / Q000601:surgery; D006801:Humans; D006835:Hydrazones / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011724:Pyridazines / Q000008:administration & dosage* / Q000009:adverse effects; D000077464:Simendan; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy*; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D000077464:Simendan